Eli Lilly and Company (LLY)
NYSE: LLYHealthcareDrug Manufacturers - GeneralUSD
Market open · Delayed 15 min · as of Oct 7, 3:31 PM ET
LLY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.06T
- P/E (TTM)
- 39.88
- Forward P/E
- 24.96
- EPS (TTM)
- $29.79
- Dividend yield
- 0.54% ($6.46)
- Ex-dividend date
- Aug 14, 2026
- 52-week range
- 783.85 – 1,292.65
- Day range
- 1,166.00 – 1,206.63
- Volume / Avg
- 1.60M / 2.48M
- Beta
- —
- Shares outstanding
- 891.74M
- Next earnings
- Oct 29, 2026
52-week range
LLY stock today
Shares of Eli Lilly (LLY) are trading higher on Oct 7 at $1,187.95, a gain of 2.63% or $30.46 per share, versus the S&P 500's 0.26% decline. Shares are 8.1% below their 52-week high of $1,292.65, set on Aug 19, 2026 and 51.6% above the 52-week low of $783.85, in the middle of the past year's range. LLY is up 11.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 41.8%.
At 39.9x trailing earnings, Eli Lilly trades above the peer-group median of 25.5x. Its forward P/E of 25.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Eli Lilly's next earnings report is expected on Oct 29, 2026. Eli Lilly pays an annual dividend of $6.46 per share, a 0.54% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Eli Lilly
Company profileEli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Mr. David A. Ricks
- Headquarters
- Indianapolis, IN
- Employees
- 50,000
- Website
- lilly.com
Financial highlights
Full financialsIn fiscal 2025, Eli Lilly generated $65.18 billion in revenue, up 44.7% from fiscal 2024, its 8th consecutive year of revenue growth. Net income was $20.64 billion (+94.9% year over year), for a net margin of 31.7% versus a median of 21.9% in the prior 5 years. Gross margin was 83.0% (up from 81.3%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B | $45.04B | $34.12B | $28.54B | $28.32B |
| Growth | +44.70% | +32.00% | +19.56% | +0.79% | +15.40% |
| Net income | $20.64B | $10.59B | $5.24B | $6.24B | $5.58B |
| EPS (diluted) | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 |
Analyst forecast
ForecastConsensus (30 analysts)
buy
Avg. price target
$1,329.21+11.89%
- Strong buy 6
- Buy 19
- Hold 3
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $9.83
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $7.94 vs —
Dividends
Dividend history- Annual dividend
- $6.46
- Dividend yield
- 0.54%
- Last payment
- $1.73
- Ex-dividend date
- Aug 14, 2026
LLY news
All LLY news- VKTX Advances Obesity Program With New Oral Maintenance StudyNasdaqVKTX, NVO, LLY
- Can Redwire's Microgravity Pharma Work Create New Revenue Streams?NasdaqRDW, BMY, LLY
- Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?NasdaqNVO, LLY, ALT, MDGL
- The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.NasdaqMDT, LLY
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?NasdaqNVO, LLY
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?NasdaqLLY, NVO
- VKTX Down 16% in a Month: Time to Invest or Exit the Stock?NasdaqVKTX, NVO, LLY
- Pfizer vs. J&J: Comparing Growth, Patent Risks and ValuationNasdaqJNJ, PFE, NVO, LLY
Eli Lilly peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JNJJohnson & Johnson | 258.74 | +1.55% | $623.53B | vs LLY |
| ABBVAbbVie Inc. | 271.55 | +1.82% | $479.85B | vs LLY |
| MRKMerck & Company Inc. | 142.68 | +0.52% | $352.02B | vs LLY |
| NVSNovartis AG | 143.08 | +1.63% | $271.95B | vs LLY |
| AZNAstraZeneca PLC | 160.19 | +0.99% | $248.43B | vs LLY |
| AMGNAmgen Inc. | 411.31 | +2.16% | $222.36B | vs LLY |
| GILDGilead Sciences Inc. | 146.68 | +1.70% | $181.88B | vs LLY |
| NVONovo Nordisk A/S | 38.22 | +1.83% | $168.69B | vs LLY |
Indexes, lists and sector
Index membership
Appears in lists
Eli Lilly stock FAQ
What is Eli Lilly's stock price today?
LLY last traded at $1,187.95 as of Oct 7, 3:31 PM EDT, up 2.63% on the day. Prices are delayed at least 15 minutes.
Does Eli Lilly pay a dividend?
Yes. Eli Lilly pays $6.46 per share annually, a 0.54% yield. The most recent dividend of $1.73 had an ex-dividend date of Aug 14, 2026.
When is Eli Lilly's next earnings date?
Eli Lilly is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $9.83.
What is LLY's P/E ratio?
LLY trades at a trailing P/E ratio of 39.88 and a forward P/E of 24.96, compared with a median of 25.5 for its closest peers.
Is Eli Lilly in the S&P 500?
Yes. Eli Lilly (LLY) is a constituent of the S&P 500 index.
Who is Eli Lilly's CEO?
Mr. David A. Ricks is the chief executive officer of Eli Lilly and Company, which has about 50,000 employees.
Has LLY ever split its stock?
Yes. The most recent LLY stock split was a 2-for-1 split on Oct 16, 1997, one of 4 splits on record.